https://niho.sk/liecivo-rizankizumab-skyrizi-na-liecbu-pacientov-s-loziskovou-psoriazou/2024-03-23T13:02:33+01:00https://niho.sk/liecivo-daratumumab-darzalex/2024-03-23T13:06:06+01:00https://niho.sk/liecivo-daratumumab-darzalex-2/2024-03-23T13:07:06+01:00https://niho.sk/liecivo-daratumumab-darzalex-3/2024-03-23T13:10:08+01:00https://niho.sk/3-liecivo-brigatinib-alunbrig/2024-03-23T12:56:56+01:00https://niho.sk/1734-2/2024-03-23T12:54:11+01:00https://niho.sk/5-liecivo-tucitinib-tukysa/2024-03-23T12:58:36+01:00https://niho.sk/6-liecivo-darolutamid-nubeqa/2024-03-23T13:00:19+01:00https://niho.sk/7-liecivo-inklisiran-leqvio-na-liecbu-primarnej-hypercholesterolemie-alebo-zmiesanej-dyslipidemie-v-sekundarnej-prevencii-kardiovaskularnych-udalosti/2024-03-23T13:22:01+01:00https://niho.sk/8-liecivo-benralizumab-fasenra-na-liecbu-tazkej-eozinofilnej-astmy/2024-03-23T13:31:27+01:00https://niho.sk/9-liecivo-finerenon-kerendia-na-liecbu-pacientov-s-chronickou-chorobou-obliciek-spojenej-s-diabetes-mellitus-2-typu/2024-03-23T13:38:29+01:00https://niho.sk/10-liecivo-esketamin-spravato-v-kombinacii-s-ssri-alebo-snri-na-liecbu-dospelych-pacientov-s-depresivnou-poruchou-rezistentnou-na-liecbu-ktori-pocas-sucasnej-stredne-tazkej-az-tazkej-depresivnej-e/2024-03-23T13:47:42+01:00https://niho.sk/11-liecivo-abrocitinib-cibinqo-na-liecbu-stredne-tazkej-a-tazkej-atopickej-dermatitidy-u-dospelych/2024-03-30T13:48:07+01:00https://niho.sk/liecivo-tafamidis-vyndaqel-na-liecbu-dospelych-pacientov-s-transtyretinovou-amyloidozou-divokeho-typu-wild-type-s-kardiomyopatiou-wtattr-cm/2024-03-30T13:57:01+01:00https://niho.sk/liecivo-palbociklib-ibrance-v-kombinacii-s-inihibitorom-aromataz-na-liecbu-lokalne-pokrocileho-alebo-metastazujuceho-karcinomu-prsnika-v-prvej-linii/2024-03-30T14:03:33+01:00https://niho.sk/15b-liecivo-palbociklib-ibrance-na-liecbu-lokalne-pokrocileho-alebo-metastazujuceho-karcinomu-prsnika-v-kombinacii-s-fulvestrantom-u-zien-ktore-podstupili-endokrinnu-liecbu/2024-03-30T14:06:14+01:00https://niho.sk/16a-liecivo-enzalutamid-xtandi-v-liecbe-dospelych-muzov-s-metastatickym-hormonalne-citlivym-karcinomom-prostaty-mhspc-v-kombinacii-s-androgennou-deprivacnou-terapiou/2024-03-30T14:14:46+01:00https://niho.sk/16b-liecivo-enzalutamid-xtandi-na-liecbu-nemetastatickeho-kastracne-rezistentneho-karcinomu-prostaty-nmcrpc/2024-03-30T14:14:23+01:00https://niho.sk/16c-liecivo-enzalutamid-xtandi-na-liecbu-dospelych-muzov-s-metastazujucim-crpc-mcrpc-u-ktorych-doslo-k-progresii-ochorenia-pocas-liecby-alebo-po-liecbe-docetaxelom/2024-03-30T14:16:39+01:00https://niho.sk/17-kombinacia-lieciv-dabrafenib-tafinlar-a-trametinib-mekinist-na-adjuvantnu-liecbu-melanomu-v-iii-stadiu-s-mutaciou-v600-genu-braf-po-kompletnej-resekcii/2024-03-30T14:25:14+01:00https://niho.sk/18a-liecivo-abemaciklib-liek-verzenios-v-kombinacii-s-tamoxifenom-alebo-inhibitormi-aromatazy-na-adjuvantnu-liecbu-pacientov-s-vcasnym-hr-her2-karcinomom-prsnika-s-pozitivnymi-uzlinami-a-vysokym/2024-03-30T14:53:20+01:00https://niho.sk/18b-liecivo-abemaciklib-liek-verzenios-v-kombinacii-s-inhibitorom-aromatazy-v-1-linii-liecby-u-pacientov-s-lokalne-pokrocilym-alebo-metastatickym-hr-her2-karcinomom-prsnika/2024-03-30T14:52:38+01:00https://niho.sk/18c-liecivo-abemaciklib-liek-verzenios-v-kombinacii-s-fulvestrantom-v-1-a-2-linii-liecby-u-pacientov-s-lokalne-pokrocilym-alebo-metastatickym-hr-her2-karcinomom-prsnika-so-skorym-nastupom-relap/2024-03-30T14:56:33+01:00https://niho.sk/19a-liecivo-nintedanib-liek-ofev-na-liecbu-intersticialnych-plucnych-ochoreni-s-progresivnym-fenotypom/2024-03-30T15:01:52+01:00https://niho.sk/19b-liecivo-nintedanib-liek-ofev-na-liecbu-dospelych-pacientov-s-idiopatickou-plucnou-fibrozou/2024-03-30T15:04:07+01:00https://niho.sk/20-sofosbuvir-a-velpatasvir-epclusa-na-liecbu-chronickej-hepatitidy-c-u-deti-vo-veku-3-rokov-a-starsich-a-dospelych-bez-cirhozy-alebo-v-stadiu-kompenzovanej-cirhozy/2024-03-30T15:09:49+01:00https://niho.sk/21b-liecivo-tisagenlekleucel-kymriah-na-liecbu-dospelych-pacientov-s-relabujucim-alebo-refrakternym-difuznym-velkobunkovym-lymfomom-b-buniek-dlbcl-po-dvoch-alebo-viacerych-liniach-systemovej-liec/2024-03-30T15:16:52+01:00https://niho.sk/liecivo-tisagenlekleucel-kymriah-na-liecbu-pediatrickych-a-mladych-dospelych-pacientov-vo-veku-do-25-rokov-vratane-s-b-bunkovou-akutnou-lymfoblastovou-leukemiou-b-all-ktora-je-refrakterna-v-rel/2024-03-30T15:19:25+01:00https://niho.sk/22a-liecivo-emicizumab-hemlibra-pri-profylaxii-krvacania-u-pacientov-vo-vsetkych-vekovych-skupinach-s-hemofiliou-a-s-inhibitorom-faktora-viii/2024-03-30T16:00:39+01:00https://niho.sk/22b-liecivo-emicizumab-hemlibra-pri-profylaxii-krvacania-u-pacientov-vo-vsetkych-vekovych-skupinach-s-tazkou-hemofiliou-a-bez-inhibitora-faktora-viii/2024-03-30T16:09:09+01:00https://niho.sk/23-liecivo-axikabtagen-ciloleucel-yescarta-na-liecbu-dospelych-pacientov-s-recidivujucim-alebo-refrakternym-difuznym-velkobunkovym-b-lymfomom-dlbcl-a-primarnym-mediastinalnym-velkobunkovym-b-lymf/2024-03-30T16:13:30+01:00https://niho.sk/24-lieciva-tixagevimab-a-cilgavimab-evusheld-na-preexpozicnu-profylaxiu-ochorenia-covid-19/2024-03-30T16:36:04+01:00https://niho.sk/25-liecivo-andexanet-alfa-ondexxya-na-liecbu-zivot-ohrozujuceho-krvacaveho-stavu-alebo-pri-potrebe-okamziteho-neodkladneho-chirurgickeho-vykonu-u-pacientov-uzivajucich-xabany/2024-03-30T16:30:29+01:00https://niho.sk/26a-liecivo-atezolizumab-tecentriq-na-liecbu-nemalobunkoveho-karcinomu-pluc-v-adjuvantnom-rezime-po-kompletnej-resekcii-a-po-chemoterapii-na-baze-platiny/2024-08-01T14:14:23+02:00https://niho.sk/26b-liecivo-atezolizumab-tecentriq-na-liecbu-prvej-linie-metastatickeho-nemalobunkoveho-karcinomu-pluc/2024-08-01T14:14:12+02:00https://niho.sk/26c-liecivo-atezolizumab-tecentriq-na-liecbu-lokalne-pokrocileho-alebo-metastatickeho-nemalobunkoveho-karcinomu-pluc-po-predchadzajucej-chemoterapii/2024-08-01T14:13:52+02:00https://niho.sk/26d-liecivo-atezolizumab-tecentriq-v-kombinacii-s-bevacizumabom-na-liecbu-dospelych-pacientov-s-hepatocelularnym-karcinomom/2024-08-01T14:13:29+02:00https://niho.sk/27-liecivo-polatuzumab-vedotin-polivy-v-kombinacii-s-rituximabom-cyklofosfamidom-doxorubicinom-a-prednizonom-r-chp-na-liecbu-dospelych-pacientov-s-predtym-neliecenym-difuznym/2024-03-30T16:51:10+01:00https://niho.sk/28-liecivo-pembrolizumab-keytruda-v-monoterapii-alebo-v-kombinacii-s-chemoterapiou-obsahujucou-platinu-a-5-fluoruracil-v-prvej-linii-metastatickeho-alebo-neresekovatelneho-rekurentneho-skvamocelula/2024-03-30T17:23:37+01:00https://niho.sk/29a-liecivo-onasemnogen-abeparvovek-zolgensma-na-liecbu-pacientov-s-5q-spinalnou-muskularnou-atrofiou-sma-s-bialelickou-mutaciou-v-gene-smn1-a-klinicky-diagnostikovanou-sma-1-typu/2024-03-30T17:27:06+01:00https://niho.sk/29b-liecivo-onasemnogen-abeparvovek-zolgensma-na-liecbu-presymptomatickych-pacientov-s-5q-sma-s-bialelickou-mutaciou-v-gene-smn1-az-do-3-kopii-genu-smn2/2024-03-30T17:28:51+01:00https://niho.sk/30a-liecivo-olaparib-lynparza-na-udrziavaciu-liecbu-rekurentneho-na-platinu-odpovedajuceho-karcinomu-vajecnikov-alebo-karcinomu-fallopiovej-trubice-alebo-peritonealneho-karcinomu-s-pritomnostou/2024-03-30T17:32:26+01:00https://niho.sk/30b-liecivo-olaparib-lynparza-v-monoterapii-na-adjuvantnu-liecbu-dospelych-pacientov-s-vysokorizikovym-vcasnym-trojnasobne-negativnym-karcinomom-prsnika-s-germinativnymi-mutaciami-brca1-2/2024-03-30T17:33:56+01:00https://niho.sk/30-liecivo-olaparib-lynparza-v-monoterapii-v-1-linii-liecby-lokalne-pokrocileho-alebo-metastatickeho-her2-negativneho-karcinomu-prsnika-s-germinativnymi-mutaciami-brca1-2/2024-03-30T17:35:55+01:00https://niho.sk/liecivo-trastuzumab-deruxtekan-enhertu-na-liecbu-pacientov-s-neresekovatelnym-alebo-metastatickym-her2-pozitivnym-karcinomom-prsnika-ktori-podstupili-jeden-alebo-viac-anti-her2-rezimov/2024-03-30T17:39:24+01:00https://niho.sk/32-liecivo-rimegepant-vydura-na-akutnu-liecbu-migreny-u-dospelych/2024-03-30T17:43:55+01:00https://niho.sk/33-liecivo-ibrutinib-imbruvica-v-kombinacii-s-venetoklaxom-na-liecbu-dospelych-pacientov-s-doposial-neliecenou-chronickou-lymfocytovou-leukemiou/2024-03-30T17:47:08+01:00https://niho.sk/34-liecivo-pembrolizumab-keytruda-v-monoterapii-na-adjuvantnu-liecbu-maligneho-melanomu/2024-03-30T17:49:42+01:00https://niho.sk/35a-liecivo-osimertinib-tagrisso-ako-monoterapia-v-adjuvantnej-liecbe-pacientov-s-nsclc-s-mutaciami-egfr/2024-03-30T17:53:50+01:00https://niho.sk/35b-liecivo-osimertinib-tagrisso-na-liecbu-dospelych-pacientov-v-prvej-linii-s-lokalne-pokrocilym-alebo-metastatickym-nemalobunkovym-karcinomom-pluc-s-aktivujucimi-mutaciami/2024-03-30T17:55:45+01:00https://niho.sk/36-liecivo-sotorasib-lumykras-na-liecbu-pacientov-s-pokrocilym-nemalobunkovym-karcinomom-pluc-nsclc-s-mutaciou-kras-g12c-v-2-a-vyssej-linii-liecby/2024-03-30T17:59:08+01:00https://niho.sk/37a-liecivo-kanabidiol-epidyolex-v-kombinacii-s-klobazamom-na-liecbu-zachvatov-spojenych-s-dravetovej-syndromom-a-lennox-gastautovym-syndromom-u-pacientov-od-2-rokov37a/2024-04-10T15:38:33+02:00https://niho.sk/37b-liecivo-kanabidiol-epidyolex-ako-adjuvantna-liecba-zachvatov-spojenych-s-komplexom-tuberoznej-sklerozy-tsc-u-pacientov-vo-veku-od-2-rokov/2024-04-10T15:40:54+02:00https://niho.sk/38-liecivo-ivakaftor-tezakaftor-a-elexakaftor-kaftrio-v-kombinacii-s-ivakaftorom-kalydeco-na-liecbu-pacientov-s-cystickou-fibrozou-cf-ktori-maju-minimalne-jednu-mutaciu-f508del-na-gene-pre-t/2024-04-10T15:47:10+02:00https://niho.sk/39-liecivo-pembrolizumab-keytruda-v-kombinacii-s-chemoterapiou-ako-neoadjuvantna-liecba-s-naslednym-pokracovanim-vo-forme-adjuvantnej-liecby-u-dospelych-s-trojnasobne-negativnym-karcinomom-prsnika/2024-04-10T15:52:07+02:00https://niho.sk/40a-liecivo-brexukabtagen-autoleucel-tecartus-na-liecbu-pacientov-vo-veku-26-rokov-a-starsich-s-recidivujucou-alebo-refrakternou-akutnou-lymfoblastickou-leukemiou-all-b-bunkovych-prekurzorov/2024-04-10T16:05:26+02:00https://niho.sk/40b-liecivo-brexukabtagen-autoleucel-tecartus-na-liecbu-dospelych-pacientov-s-recidivujucim-alebo-refrakternym-lymfomom-z-plastovych-buniek-mcl-po-dvoch-alebo-viacerych-liniach/2024-04-10T16:10:33+02:00https://niho.sk/41-liecivo-daratumumab-darzalex-v-kombinacii-s-lenalidomidom-a-dexametazonom-na-liecbu-dospelych-pacientov-s-novodiagnostikovanym-mnohopocetnym-myelomom-ktori-nie-su-vhodni-na-autolognu-transplant/2024-04-10T16:14:02+02:00https://niho.sk/42a-liecivo-emicizumab-hemlibra-pri-profylaxii-krvacania-u-pacientov-vo-vsetkych-vekovych-skupinach-s-hemofiliou-a-s-inhibitorom-faktora-viii/2024-04-10T16:16:16+02:00https://niho.sk/42b-liecivo-emicizumab-hemlibra-pri-profylaxii-krvacania-u-pacientov-vo-vsetkych-vekovych-skupinach-s-tazkou-hemofiliou-a-bez-inhibitora-faktora-viii/2024-04-10T16:18:02+02:00https://niho.sk/43a-liecivo-ekulizumab-soliris-na-liecbu-pacientov-s-refrakternou-generalizovanou-myasteniou-gravis/2024-04-10T16:22:31+02:00https://niho.sk/43b-liecivo-ekulizumab-soliris-na-liecbu-neuromyelitis-optica-a-jej-spektra-ochoreni-nmosd/2024-04-10T16:24:05+02:00https://niho.sk/44-liecivo-darolutamid-nubeqa-na-liecbu-metastatickeho-hormonalne-citliveho-karcinomu-prostaty-v-kombinacii-s-adt-a-docetaxelom-u-dospelych-muzov/2024-04-10T16:26:07+02:00https://niho.sk/45-liecivo-brentuximab-vedotin-adcetris-v-kombinacii-s-doxorubicinom-vinblastinom-a-dakarbazinom-avd-na-liecbu-dospelych-pacientov-s-predtym-neliecenym-cd30-pozitivnym-hodgkinovym-lymfomom-v-sta/2024-04-10T16:32:53+02:00https://niho.sk/46-liecivo-tebentafusp-kimmtrak-na-liecbu-dospelych-pacientov-s-neresekovatelnym-alebo-metastatickym-uvealnym-melanomom/2024-04-10T16:36:30+02:00https://niho.sk/47-liecivo-efgartigimod-alfa-vyvgart-na-liecbu-myastenie-gravis/2024-04-10T16:45:14+02:00https://niho.sk/48-liecivo-nirmatrelvir-a-ritonavir-paxlovid-na-liecbu-dospelych-vysokorizikovych-pacientov-s-ochorenim-covid-19/2024-04-10T16:50:02+02:00https://niho.sk/49-liecivo-maribavir-livtencity-na-liecbu-refrakternej-cytomegalovirusovej-cmv-infekcie-a-alebo-choroby-po-transplantacii-hematopoetickych-kmenovych-buniek-alebo-solidnych-organov/2024-04-10T16:55:02+02:00https://niho.sk/50-liecivo-kyselina-obeticholova-ocaliva-na-liecbu-primarnej-biliarnej-cholangitidy/2024-04-10T17:01:54+02:00https://niho.sk/51-liecivo-pembrolizumab-keytruda-na-liecbu-dospelych-pacientov-s-metastatickym-kolorektalnym-karcinomom/2024-04-10T17:04:22+02:00https://niho.sk/52-liecivo-sacituzumab-govitekan-trodelvy-na-liecbu-dospelych-pacientov-s-pokrocilym-trojito-negativnym-karcinomom-prsnika-ktori-podstupili-dve-alebo-viac-systemovych-terapii/2024-04-10T17:09:38+02:00https://niho.sk/54b-liecivo-upadacitinib-rinvoq-na-liecbu-dospelych-pacientov-so-stredne-tazkou-az-tazkou-aktivnou-crohnovou-chorobou-po-predoslej-konvencnej-a-biologickej-liecbe/2024-04-10T17:14:29+02:00https://niho.sk/54a-liecivo-upadacitinib-rinvoq-na-liecbu-dospelych-pacientov-so-stredne-tazkou-az-tazkou-aktivnou-ulceroznou-kolitidou-po-predoslej-konvencnej-a-biologickej-liecbe/2024-04-10T17:55:51+02:00https://niho.sk/55-liecivo-empagliflozin-jardiance-na-liecbu-dospelych-pacientov-s-chronickou-chorobou-obliciek/2024-04-10T18:03:52+02:00https://niho.sk/56-liecivo-pembrolizumab-keytruda-v-kombinacii-s-chemoterapiou-obsahujucou-pemetrexed-a-platinu-na-liecbu-dospelych-pacientov-v-prvej-linii-metastatickeho-neskvamozneho-nemalobunkoveho-karcinomu-pl/2024-04-10T18:06:09+02:00https://niho.sk/57-liecivo-nivolumab-opdivo-v-monoterapii-na-liecbu-dospelych-pacientov-s-pokrocilym-karcinomom-z-renalnych-buniek-po-predchadzajucej-liecbe/2025-02-08T22:05:24+01:00https://niho.sk/12a-liecivo-nivolumab-opdivo-v-monoterapii-na-liecbu-pokrocileho-neresektovatelneho-alebo-metastatickeho-melanomu/2024-11-23T18:10:34+01:00https://niho.sk/12b-liecivo-nivolumab-opdivo-na-liecbu-pacientov-s-pokrocilym-karcinomom-z-renalnych-buniek-v-druhej-alebo-tretej-linii/2024-11-23T18:21:30+01:00https://niho.sk/13a-liecivo-ribociklib-kisqali-v-kombinacii-s-inhibitorom-aromatazy-v-prvej-linii-liecby-metastatickeho-hr-her2-karcinomu-prsnika/2024-11-30T17:01:00+01:00https://niho.sk/13b-liecivo-ribociklib-kisqali-v-kombinacii-s-fulvestrantom-v-prvej-linii-liecby-pokrocileho-hr-her2-karcinomu-prsnika-so-skorym-nastupom-relapsu-alebo-progresie-ochorenia-od-ukoncenia-neo/2024-12-04T17:37:56+01:00